Fact CheckerSign in

NCT07706335Not yet recruiting

Insulin Resistance and Its Association With no Reflow Phenomenon After Primary PCI in Type II Diabetic STEMI Patients.

Source: ClinicalTrials.gov · Last updated 16 Jul 2026

Brief summary (registry, in English)

To investigate the relationship between the TyG index, coronary lesion complexity assessed by the SYNTAX score, and the development of the no-reflow phenomenon in STEMI patients with T2DM.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
100 (estimated)
First submitted
11 Jul 2026
Start date
1 Aug 2026
Primary completion date
1 Aug 2028
Lead sponsor
Assiut University
NCT number
NCT07706335

What you commit to

  • Study type: Observational
  • Planned participants: 100
  • From 1 Aug 2026 to the primary completion date, 1 Aug 2028
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Lab values

  • 1\. Individuals with a previous history of myocardial infarction (MI) or decompensated heart failure.
    • 2\. Individuals with Cardiogenic shock. 3. Individuals with a history of PCI or coronary artery bypass grafting (CABG). 4.Previous familial mixed dyslipidemia / Hypertriglycerideemia (Homozygous or heterozygous).
    • 5.Patients with significant hepatic impairment (transaminase levels ≥ 2x normal value).
    • 6.Patients with renal impairment (GFR \< 60 mL/min/1.73 m²). 7.Active infection or inflammatory disease. 8.Known autoimmune disease. 9.Malignancy. 10. Type 1 Diabetes Mellitus patients.

Who the study is looking for

  • Age ≥ 18 years
  • Type 2 Diabetes Mellitus patients .
  • Undergoing PCI for STEMI.
  • Written informed consent obtained.

Age in the registry: 18 years to 100 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.